{"id":"https://openalex.org/W1992065025","doi":"https://doi.org/10.1158/1538-7445.am2014-2397","title":"Abstract 2397: Nanoformulations of PARP inhibtors for cancer therapy","display_name":"Abstract 2397: Nanoformulations of PARP inhibtors for cancer therapy","publication_year":2014,"publication_date":"2014-10-01","ids":{"openalex":"https://openalex.org/W1992065025","doi":"https://doi.org/10.1158/1538-7445.am2014-2397","mag":"1992065025"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2014-2397","doi":"https://doi.org/10.1158/1538-7445.am2014-2397","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2014-2397","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5020321227","display_name":"Shifalika Tangutoori","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I12912129","display_name":"Northeastern University","ror":"https://ror.org/04t5xt781","country_code":"US","type":"education","lineage":["https://openalex.org/I12912129"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shifalika Tangutoori","raw_affiliation_strings":["1Northeastern University, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Northeastern University, Boston, MA;","institution_ids":["https://openalex.org/I12912129"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033547791","display_name":"Paige Baldwin","orcid":"https://orcid.org/0000-0002-0146-7177","observed_orcids":["https://orcid.org/0000-0002-0146-7177"]},"institutions":[{"id":"https://openalex.org/I12912129","display_name":"Northeastern University","ror":"https://ror.org/04t5xt781","country_code":"US","type":"education","lineage":["https://openalex.org/I12912129"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paige Baldwin","raw_affiliation_strings":["1Northeastern University, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Northeastern University, Boston, MA;","institution_ids":["https://openalex.org/I12912129"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089283632","display_name":"Houari Korideck","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Houari Korideck","raw_affiliation_strings":["2Dana Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Dana Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088554776","display_name":"Robert A. Cormack","orcid":"https://orcid.org/0000-0001-5553-9984","observed_orcids":["https://orcid.org/0000-0001-5553-9984"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert Cormack","raw_affiliation_strings":["2Dana Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Dana Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039898021","display_name":"Mike G. Makrigiorgos","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mike G. Makrigiorgos","raw_affiliation_strings":["2Dana Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Dana Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5101987852","display_name":"Srinivas Sridhar","orcid":"https://orcid.org/0000-0003-1605-0734","observed_orcids":["https://orcid.org/0000-0003-1605-0734"]},"institutions":[{"id":"https://openalex.org/I12912129","display_name":"Northeastern University","ror":"https://ror.org/04t5xt781","country_code":"US","type":"education","lineage":["https://openalex.org/I12912129"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Srinivas Sridhar","raw_affiliation_strings":["1Northeastern University, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Northeastern University, Boston, MA;","institution_ids":["https://openalex.org/I12912129"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"74","issue":"19_Supplement","first_page":"2397","last_page":"2397"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.7261000275611877,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.7261000275611877,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.2542000114917755,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11176","display_name":"Radiation Therapy and Dosimetry","score":0.0044999998062849045,"subfield":{"id":"https://openalex.org/subfields/3108","display_name":"Radiation"},"field":{"id":"https://openalex.org/fields/31","display_name":"Physics and Astronomy"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.9909999966621399},{"id":"https://openalex.org/keywords/olaparib","display_name":"olaparib","score":0.9679999947547913},{"id":"https://openalex.org/keywords/talazoparib","display_name":"talazoparib","score":0.9700000286102295},{"id":"https://openalex.org/keywords/nanoparticle-drug-delivery","display_name":"nanoparticle drug delivery","score":0.8690000176429749},{"id":"https://openalex.org/keywords/nanoformulations","display_name":"nanoformulations","score":0.6819999814033508},{"id":"https://openalex.org/keywords/radiosensitization","display_name":"radiosensitization","score":0.9509999752044678},{"id":"https://openalex.org/keywords/cisplatin-combination-therapy","display_name":"cisplatin combination therapy","score":0.7979999780654907},{"id":"https://openalex.org/keywords/synthetic-lethality","display_name":"synthetic lethality","score":0.8289999961853027},{"id":"https://openalex.org/keywords/brca-mutations","display_name":"BRCA mutations","score":0.878000020980835},{"id":"https://openalex.org/keywords/prostate-cancer","display_name":"prostate cancer","score":0.8889999985694885},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.8330000042915344},{"id":"https://openalex.org/keywords/ovarian-cancer","display_name":"ovarian cancer","score":0.9990000128746033},{"id":"https://openalex.org/keywords/tmprss2-erg-fusion","display_name":"TMPRSS2-ERG fusion","score":0.7979999780654907},{"id":"https://openalex.org/keywords/poly-adp-ribosyl-ation","display_name":"poly(ADP-ribosyl)ation","score":0.671999990940094},{"id":"https://openalex.org/keywords/gamma-h2ax","display_name":"\u03b3H2AX","score":0.8240000009536743},{"id":"https://openalex.org/keywords/rad51","display_name":"RAD51","score":0.8679999709129333},{"id":"https://openalex.org/keywords/isobologram-analysis","display_name":"isobolographic analysis","score":0.6240000128746033}],"concepts":[{"id":"https://openalex.org/C2779962180","wikidata":"https://www.wikidata.org/wiki/Q7083106","display_name":"Olaparib","level":5,"score":0.9645372629165649},{"id":"https://openalex.org/C2779138821","wikidata":"https://www.wikidata.org/wiki/Q7118227","display_name":"PARP inhibitor","level":5,"score":0.7473862767219543},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6418207883834839},{"id":"https://openalex.org/C117262875","wikidata":"https://www.wikidata.org/wiki/Q5135057","display_name":"Clonogenic assay","level":3,"score":0.5971677303314209},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.5930436849594116},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5656537413597107},{"id":"https://openalex.org/C2780427987","wikidata":"https://www.wikidata.org/wiki/Q172341","display_name":"Ovarian cancer","level":3,"score":0.5233615636825562},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.5017504692077637},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.48998919129371643},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4384256899356842},{"id":"https://openalex.org/C2778502085","wikidata":"https://www.wikidata.org/wiki/Q7662767","display_name":"Synthetic lethality","level":4,"score":0.432280570268631},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.4190678894519806},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.32368046045303345},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3050702214241028},{"id":"https://openalex.org/C182979987","wikidata":"https://www.wikidata.org/wiki/Q3907241","display_name":"Poly ADP ribose polymerase","level":4,"score":0.29101037979125977},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.24958813190460205},{"id":"https://openalex.org/C134935766","wikidata":"https://www.wikidata.org/wiki/Q210538","display_name":"DNA repair","level":3,"score":0.21462658047676086},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.20833632349967957},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2016650140285492},{"id":"https://openalex.org/C82381507","wikidata":"https://www.wikidata.org/wiki/Q416878","display_name":"Polymerase","level":3,"score":0.11035695672035217},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2014-2397","doi":"https://doi.org/10.1158/1538-7445.am2014-2397","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2014-2397","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2563544855","https://openalex.org/W2566054689","https://openalex.org/W2079215618","https://openalex.org/W7070521202","https://openalex.org/W2504216116","https://openalex.org/W2403569294","https://openalex.org/W2399980135","https://openalex.org/W2789470100","https://openalex.org/W2528345273","https://openalex.org/W7060780813"],"abstract_inverted_index":{"Abstract":[0],"Introduction:":[1],"Poly":[2],"ADP":[3],"Ribose":[4],"Polymerase":[5],"inhibitor":[6],"therapy":[7,190,239],"(PARPi)":[8],"exploits":[9],"a":[10,46,79,83,185,307,368],"synthetic":[11],"lethality":[12],"strategy":[13],"in":[14,21,41,52,55,113,143,295,342,371],"cancers":[15,115],"specifically":[16,89],"endowed":[17],"with":[18,124,156,172,240,289,344,351,374],"inherent":[19],"damage":[20],"DNA":[22],"repair":[23],"or":[24,175],"transcription":[25],"pathways.":[26],"Olaparib":[27],"and":[28,58,65,73,111,119,125,135,141,158,170,178,200,228,237,269,291,300,321,360,393,398],"BMN-673":[29,74,176],"are":[30,35,353],"potent":[31],"PARP":[32,421],"inhibitors":[33],"that":[34],"currently":[36],"indicated":[37],"for":[38,45,70,86,107,217,316,390,423,438],"oral":[39],"PARPi":[40,159,236],"several":[42,114,146,192,382,401],"clinical":[43],"trials":[44],"variety":[47],"of":[48,188,234,256,266,285,420,429,434],"cancers.":[49],"Oral":[50],"administration":[51],"general":[53],"results":[54,385],"poor":[56],"bioavailability":[57,97],"tumor":[59],"accumulation.":[60],"Here":[61],"we":[62],"report":[63],"novel":[64],"well":[66],"characterized":[67],"nanoformulations":[68,160],"customized":[69],"olaparib":[71,173],"(NanoOlaparib)":[72],"(NanoBMN)":[75],",":[76],"thus":[77],"enabling":[78,400],"platform":[80,242],"which":[81,305],"provides":[82],"safe":[84],"vehicle":[85],"intravenous":[87],"delivery":[88],"targeted":[90],"to":[91,209,327],"the":[92,96,108,127,261,328,372,391,430,435],"tumor,":[93],"thereby":[94],"increasing":[95],"while":[98],"reducing":[99],"systemic":[100],"toxicity.":[101],"Our":[102],"nanoplatform":[103],"is":[104],"also":[105],"tailored":[106],"combinatorial":[109],"chemotherapy":[110],"radio-sensitization":[112],"including":[116,250],"prostate,":[117],"ovarian":[118,246],"breast":[120,229],"cancer":[121,147,230,247,297,424],"cell":[122,148,193,248,283,302,330],"lines":[123,194,249,331],"without":[126],"BRCA":[128],"mutations.":[129],"Methods:":[130],"Two":[131],"nanoparticle":[132,241,357],"formulations":[133,258,358,395],"NanoOlaparib":[134,319,338,359],"NanoBMN":[136],"have":[137,362],"been":[138,363],"successfully":[139,364],"formulated":[140],"tested":[142,332],"vitro":[144],"on":[145,191,226,245,259],"lines.":[149,303],"The":[150,206,232,254],"initial":[151],"combination":[152,235,343],"studies":[153,337,350],"were":[154,195,202],"performed":[155],"Cisplatin":[157],"defined":[161],"by":[162,264,273],"\u223c163":[163],"nm":[164],"diameter,":[165],"zeta":[166],"potential":[167],"\u223c":[168],"+10mV,":[169],"loaded":[171],"(2.3mM)":[174],"(200\u00b5M)":[177],"cisplatin":[179],"(\u223c3.3mM).":[180],"Dose":[181],"response":[182],"curves":[183],"over":[184],"dynamic":[186],"range":[187],"nanoPARPi":[189],"generated":[196],"using":[197,204,211,220,318],"MTS":[198],"assay":[199],"EC50's":[201],"determined":[203,244,272],"Prism.":[205],"synergism":[207],"due":[208],"radiosensitization":[210,378],"220":[212],"keV":[213],"beam":[214],"was":[215,243,271,311,379],"studied":[216],"both":[218,375],"therapies":[219],"isobolograms":[221],"developed":[222],"from":[223],"clonogenic":[224],"assays":[225],"prostate":[227,296],"cells.":[231],"efficacy":[233,341,373],"Pt":[238],"PA-1,":[251],"KURAMOCHI":[252],"etc.":[253],"functionality":[255],"nanoPARPi/combination":[257],"all":[260,336],"cancers,":[262],"reflected":[263],"inhibition":[265],"PARylation,":[267],"\u03b3-H2AX":[268],"RAD-51":[270],"immunoflourescence":[274],"assays.":[275],"Results:":[276],"Radiosensitization":[277],"showed":[278,339],"strong":[279],"radiosensitization,":[280],"achieving":[281],"long-term":[282],"kill":[284],"more":[286,312],"than":[287,314,346],"90%":[288],"NanOlaparib":[290],"4":[292],"Gy":[293],"radiation":[294,324,345],"PC3,":[298],"VCaP":[299,304],"LNCaP":[301],"carries":[306],"TMPRSS2:":[308],"ERG":[309],"fusion":[310],"responsive":[313],"PC3":[315],"monotherapy":[317],"alone,":[320],"had":[322],"better":[323,340],"sensitization":[325],"compared":[326],"other":[329],"so":[333],"far.":[334],"In":[335],"free":[347],"Olaparib.":[348],"Similar":[349],"nanoBMN":[352,394],"underway.":[354],"Conclusions:":[355],"Robust":[356],"NanoOlaparibPt":[361],"demonstrated.":[365],"We":[366],"observed":[367,380],"significant":[369],"enhancement":[370],"nanoformulations.":[376],"Strong":[377],"after":[381],"days.":[383],"These":[384],"imply":[386],"an":[387],"important":[388],"role":[389],"nanoOlaparib":[392],"as":[396],"chemo":[397],"radio-sensitizers":[399],"therapeutic":[402],"approaches.":[403],"Citation":[404],"Format:":[405],"Shifalika":[406],"Tangutoori,":[407],"Paige":[408],"Baldwin,":[409],"Houari":[410],"Korideck,":[411],"Robert":[412],"Cormack,":[413],"Mike":[414],"G.":[415],"Makrigiorgos,":[416],"Srinivas":[417],"Sridhar.":[418],"Nanoformulations":[419],"inhibtors":[422],"therapy.":[425],"[abstract].":[426],"In:":[427],"Proceedings":[428],"105th":[431],"Annual":[432],"Meeting":[433],"American":[436],"Association":[437],"Cancer":[439,450],"Research;":[440],"2014":[441],"Apr":[442],"5-9;":[443],"San":[444],"Diego,":[445],"CA.":[446],"Philadelphia":[447],"(PA):":[448],"AACR;":[449],"Res":[451],"2014;74(19":[452],"Suppl):Abstract":[453],"nr":[454],"2397.":[455],"doi:10.1158/1538-7445.AM2014-2397":[456]},"counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-11-03T10:50:19.383937","created_date":"2016-06-24T00:00:00"}